Skip to main content
SpringerLink
Log in

Introduction to Cancer Treatment

  • Living reference work entry
  • First Online:
Handbook of Cancer and Immunology

  • 63 Accesses

Abstract

Cancer is defined as the outrageous growth of cells in a part of the body. It is one of the most common causes of death and its burden is on the rise all over the world. Breast cancer is the most common cause of death among all cancer types. Traditional cancer treatments are surgery, radiation therapy, and chemotherapy. Cancer immunotherapy is another new approach to the treatment of cancer, which in general means the potentiation of the immune system against cancer. It is mostly categorized into two subgroups: passive and active immunotherapy. There are some mechanisms developed as cancer immunotherapy consisting of monoclonal antibodies (mAbs), cytokines, cancer vaccines, natural killer (NK) cell therapy, immune checkpoint blockade, chimeric antigen receptor T (CAR-T) cell therapy, and oncolytic virotherapy. In this chapter, we are going to discuss the efficacy of these treatments alone or in combination with other modalities and the current development in different cancers, including breast cancer, urologic cancers, gastrointestinal cancers, pediatric cancers, skin cancers, endocrine cancers, and lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K (2020) Immunotherapy in gastrointestinal cancer: the current scenario and future perspectives. Cancer Treat Rev 88:102030

    Article  CAS  PubMed  Google Scholar 

  • Adel N (2019) Current treatment landscape and emerging therapies for pancreatic cancer. Am J Manag Care 25:S3–S10

    PubMed  Google Scholar 

  • Alatrash G, Jakher H, Stafford PD, Mittendorf EA (2013) Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 12:631–645

    Article  CAS  PubMed  Google Scholar 

  • Audi ZF, Saker Z, Rizk M, Harati H, Fares Y, Bahmad HF, Nabha SM (2021) Immunosuppression in Medulloblastoma: insights into cancer immunity and immunotherapy. Curr Treat Options in Oncol 22:83

    Article  Google Scholar 

  • Batool A, Karimi N, Wu XN, Chen SR, Liu YX (2019) Testicular germ cell tumor: a comprehensive review. Cell Mol Life Sci 76:1713–1727

    Article  CAS  PubMed  Google Scholar 

  • Binder S, Luciano M, Horejs-Hoeck J (2018) The cytokine network in acute myeloid leukemia (Aml): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev 43:8–15

    Article  CAS  PubMed  Google Scholar 

  • Blank CU, Enk A (2015) Therapeutic use of anti-Ctla-4 antibodies. Int Immunol 27:3–10

    Article  CAS  PubMed  Google Scholar 

  • Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, Li P, Lyu N, Sun T, Xie S, Guo L, Ni L, Jin L, Dong C (2020) Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to Pd-1 blockade therapy. Cell Mol Immunol 17:227–236

    Article  CAS  PubMed  Google Scholar 

  • Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 134:783–791

    Article  PubMed  PubMed Central  Google Scholar 

  • Carosella ED, Ploussard G, Lemaoult J, Desgrandchamps F (2015) A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of Ctla-4, Pd-1/Pd-L1, and Hla-G. Eur Urol 68:267–279

    Article  CAS  PubMed  Google Scholar 

  • Castillejos-Molina RA, Gabilondo-Navarro FB (2016) Prostate cancer. Salud Publica Mex 58:279–284

    Article  PubMed  Google Scholar 

  • Chen FZ, Zhao XK (2013) Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J 15:279–284

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA (2014) A feasibility study of cyclophosphamide, Trastuzumab, and an allogeneic Gm-Csf-secreting breast tumor vaccine for Her2+ metastatic breast cancer. Cancer Immunol Res 2:949–961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen X, Kunda PE, Lin J, Zhou M, Huang J, Zhang H, Liu T (2018) Syk-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma. J Cancer Res Clin Oncol 144:675–684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W (2021) Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 500:1–10

    Article  CAS  PubMed  Google Scholar 

  • Cimino-Mathews A, Foote JB, Emens LA (2015) Immune targeting in breast cancer. Oncology (Williston Park) 29:375–385

    PubMed  Google Scholar 

  • Colunga A, Pulliam T, Nghiem P (2018) Merkel cell carcinoma in the age of immunotherapy: facts and hopes. Clin Cancer Res 24:2035–2043

    Article  CAS  PubMed  Google Scholar 

  • Coussens LM, Pollard JW (2011) Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol 3(3):a003285. https://doi.org/10.1101/cshperspect.a003285. PMID: 21123394; PMCID: PMC3039933.

  • Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF (2018) Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 74:784–795

    Article  PubMed  Google Scholar 

  • Dai C, Liang S, Sun B, Kang J (2020) The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne) 11:608422

    Article  PubMed  Google Scholar 

  • Denardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9:212

    Article  PubMed  PubMed Central  Google Scholar 

  • Denardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) Cd4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, Dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG (2009) Concurrent Trastuzumab and Her2/Neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685–4692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eltabbakh GH, Awtrey CS (2001) Current treatment for ovarian cancer. Expert Opin Pharmacother 2:109–124

    Article  CAS  PubMed  Google Scholar 

  • Emens LA (2012) Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 12:1597–1611

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Emens LA (2018) Breast cancer immunotherapy: facts and hopes. Clin Cancer Res 24:511–520

    Article  CAS  PubMed  Google Scholar 

  • Faria SC, Devine CE, Rao B, Sagebiel T, Bhosale P (2019) Imaging and staging of endometrial cancer. Semin Ultrasound CT MR 40:287–294

    Article  CAS  PubMed  Google Scholar 

  • Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V (2018) Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol 9:398

    Article  PubMed  PubMed Central  Google Scholar 

  • Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K (2020) Epidemiology of ovarian cancer. Chin Clin Oncol 9:47

    Article  PubMed  Google Scholar 

  • Gombos DS, Chevez-Barrios AP (2007) Current treatment and management of retinoblastoma. Curr Oncol Rep 9:453–458

    Article  PubMed  Google Scholar 

  • Grupp SA, Verneris M, Sondel PM, Cooper LJ (2008) Immunotherapy for pediatric cancer. Biol Blood Marrow Transplant 14:33–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hartl CA, Bertschi A, Puerto RB, Andresen C, Cheney EM, Mittendorf EA, Guerriero JL, Goldberg MS (2019) Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. J Immunother Cancer 7:199

    Article  PubMed  PubMed Central  Google Scholar 

  • Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, Mcmahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL (2015) Docetaxel alone or in combination with a therapeutic cancer vaccine (Panvac) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol 1:1087–1095

    Article  PubMed  PubMed Central  Google Scholar 

  • Ho PC, Kaech SM (2017) Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol 46:38–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hochberg J, El-Mallawany NK, Cairo MS (2014) Humoral and cellular immunotherapy in all in children, adolescents, and young adults. Clin Lymphoma Myeloma Leuk 14(Suppl):S6–S13

    Article  PubMed  Google Scholar 

  • Hofmann S, Schubert ML, Wang L, He B, Neuber B, Dreger P, Müller-Tidow C, Schmitt M (2019) Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). J Clin Med 8(2):200. https://doi.org/10.3390/jcm8020200. PMID: 30736352; PMCID: PMC6406805.

  • Hong B, Dong R (2021) Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review. Transl Cancer Res 10:1559–1567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang MA, Krishnadas DK, Lucas KG (2015) Cellular and antibody based approaches for pediatric cancer immunotherapy. J Immunol Res 2015:675269

    Article  PubMed  PubMed Central  Google Scholar 

  • Hunter AM, Sallman DA (2019) Current status and new treatment approaches in Tp53 mutated Aml. Best Pract Res Clin Haematol 32:134–144

    Article  PubMed  Google Scholar 

  • Iwai Y, Hamanishi J, Chamoto K, Honjo T (2017) Cancer immunotherapies targeting the Pd-1 signaling pathway. J Biomed Sci 24:26

    Article  PubMed  PubMed Central  Google Scholar 

  • Jelovac D, Emens LA (2013) Her2-directed therapy for metastatic breast cancer. Oncology (Williston Park) 27:166–175

    PubMed  Google Scholar 

  • Jiang T, Zhou C, Ren S (2016) Role of Il-2 in cancer immunotherapy. Onco Targets Ther 5:E1163462

    Google Scholar 

  • Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71:264–279

    Article  PubMed  PubMed Central  Google Scholar 

  • Kamali Zonouzi S, Pezeshki PS, Razi S, Rezaei N (2022) Cancer-associated fibroblasts in colorectal cancer. Clin Transl Oncol 24:757–769

    Article  CAS  PubMed  Google Scholar 

  • Kawahara M, Takaku H (2015) A tumor lysate is an effective vaccine antigen for the stimulation of Cd4(+) T-cell function and subsequent induction of antitumor immunity mediated by Cd8(+) T cells. Cancer Biol Ther 16:1616–1625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK (2006) Reversing tumor immune suppression with intratumoral Il-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of Cd8+ T effectors. J Immunol 177:6962–6973

    Article  CAS  PubMed  Google Scholar 

  • Klemen ND, Kelly CM, Bartlett EK (2021) The emerging role of immunotherapy for the treatment of sarcoma. J Surg Oncol 123:730–738

    Article  CAS  PubMed  Google Scholar 

  • Lanza F, Moretti S, Castagnari B, Montanelli F, Latorraca A, Ferrari L, Bardi A, Dominici M, Campioni D, Dabusti M, Piva N, Lodi G, Reverberi R, Castoldi G (1999) Assessment of distribution of Cd34 epitope classes in fresh and cryopreserved peripheral blood progenitor cells and acute myeloid leukemic blasts. Haematologica 84:969–977

    CAS  PubMed  Google Scholar 

  • Lei AQ, Cheng L, Pan CX (2011) Current treatment of metastatic bladder cancer and future directions. Expert Rev Anticancer Ther 11:1851–1862

    Article  CAS  PubMed  Google Scholar 

  • Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM (2018) Association of Ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncol 4:E173776

    Article  PubMed  Google Scholar 

  • Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK (2014) Peptide vaccine: progress and challenges. Vaccines (Basel) 2:515–536

    Article  CAS  PubMed  Google Scholar 

  • Liao D, Wang M, Liao Y, Li J, Niu T (2019) A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol 10:609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlović S (2006) Testing the safety of clinical-grade mature autologous myeloid Dc in a phase I clinical immunotherapy trial of cml. Cytotherapy 8:290–298

    Article  CAS  PubMed  Google Scholar 

  • Liu Q, Wang Y, Wang H, Liu Y, Liu T, Kunda PE (2013) Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol 139:1357–1372

    Article  CAS  PubMed  Google Scholar 

  • Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050–6056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Luen S, Virassamy B, Savas P, Salgado R, Loi S (2016) The genomic landscape of breast cancer and its interaction with host immunity. Breast 29:241–250

    Article  PubMed  Google Scholar 

  • Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A (2021) Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 13(17):4287. https://doi.org/10.3390/cancers13174287. PMID: 34503097; PMCID: PMC8428369

  • Lynam S, Lugade AA, Odunsi K (2020) Immunotherapy for gynecologic cancer: current applications and future directions. Clin Obstet Gynecol 63:48–63

    Article  PubMed  PubMed Central  Google Scholar 

  • Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL (2019) Car T cells targeting B7-H3, a Pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 25:2560–2574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M (2019) Lenvatinib plus Pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:711–718

    Article  CAS  PubMed  Google Scholar 

  • Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC (2019) Neoantigen screening identifies broad Tp53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest 129:1109–1114

    Article  PubMed  Google Scholar 

  • Mantziari S, Teixeira Farinha H, Bouygues V, Vignal JC, Deswysen Y, Demartines N, Schäfer M, Piessen G (2021) Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes; A Systematic Review and Pooled Analysis. Cancers (Basel). 13(9):2104. https://doi.org/10.3390/cancers13092104. PMID: 33925512; PMCID: PMC8123886.

  • Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y (2018) Induction of Neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer. Clin Cancer Res 24:5357–5367

    Article  CAS  PubMed  Google Scholar 

  • Mcglynn KA, Petrick JL, El-Serag HB (2021) Epidemiology of hepatocellular carcinoma. Hepatology 73(Suppl 1):4–13

    Article  CAS  PubMed  Google Scholar 

  • Medikonda R, Dunn G, Rahman M, Fecci P, Lim M (2021) A review of glioblastoma immunotherapy. J Neuro-Oncol 151:41–53

    Article  Google Scholar 

  • Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK (2011) Phase III multicenter clinical trial of the Sialyl-Tn (Stn)-keyhole limpet Hemocyanin (Klh) vaccine for metastatic breast cancer. Oncologist 16:1092–1100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mitra M, Kandalam M, Harilal A, Verma RS, Krishnan UM, Swaminathan S, Krishnakumar S (2012) Epcam is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis 18:290–308

    CAS  PubMed  PubMed Central  Google Scholar 

  • Miyazawa M, Katsuda M, Kawai M, Hirono S, Okada KI, Kitahata Y, Yamaue H (2021) Advances in immunotherapy for pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 28:419–430

    Article  PubMed  Google Scholar 

  • Moeinafshar A, Hemmati S, Rezaei N (2021) Immunotherapy in Aml: a brief review on emerging strategies. Clin Transl Oncol 23:2431–2447

    Article  CAS  PubMed  Google Scholar 

  • Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, Taki M, Budiman K, Zeng X, Hosoe Y, Azuma M, Konishi I, Mandai M (2019) Vista expressed in tumour cells regulates T cell function. Br J Cancer 120:115–127

    Article  CAS  PubMed  Google Scholar 

  • Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, Von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A (2015) Trastuzumab Emtansine (T-Dm1) renders Her2+ breast cancer highly susceptible to Ctla-4/Pd-1 blockade. Sci Transl Med 7:315ra188

    Article  PubMed  Google Scholar 

  • Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19–28

    Article  CAS  PubMed  Google Scholar 

  • Nizzero S, Shen H, Ferrari M, Corradetti B (2020) Immunotherapeutic transport Oncophysics: space, time, and immune activation in cancer. Trends Cancer 6:40–48

    Article  CAS  PubMed  Google Scholar 

  • Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, Mcarthur HL (2016) Deep sequencing of T-cell receptor Dna as a biomarker of clonally expanded Tils in breast cancer after immunotherapy. Cancer Immunol Res 4:835–844

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P (2016) Harnessing the immune system to improve cancer therapy. Ann Transl Med 4:261

    Article  PubMed  PubMed Central  Google Scholar 

  • Parker BS, Rautela J, Hertzog PJ (2016) Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16:131–144

    Article  PubMed  Google Scholar 

  • Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17:6287–6297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pinilla-Ibarz J, Cathcart K, Scheinberg DA (2000) Cml vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 14:111–120

    Article  CAS  PubMed  Google Scholar 

  • Qayyum T, Oades G, Horgan P, Aitchison M, Edwards J (2013) The epidemiology and risk factors for renal cancer. Curr Urol 6:169–174

    Article  PubMed  PubMed Central  Google Scholar 

  • Ribas A (2015) Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 5:915–919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ Jr (2020) Car T cells targeting Misiir for the treatment of ovarian cancer and other gynecologic malignancies. Mol Ther 28:548–560

    Article  CAS  PubMed  Google Scholar 

  • Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA (2016) Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 8:357ra123

    Article  PubMed  PubMed Central  Google Scholar 

  • Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31:666–675

    Article  PubMed  Google Scholar 

  • Rozeman EA, Dekker TJA, Haanen J, Blank CU (2018) Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol 19:303–317

    Article  PubMed  Google Scholar 

  • Schuster M, Nechansky A, Kircheis R (2006) Cancer immunotherapy. Biotechnol J 1:138–147

    Article  CAS  PubMed  Google Scholar 

  • Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E (2019) Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. Future Oncol 15:533–541

    Article  CAS  PubMed  Google Scholar 

  • Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the Egfr signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z (2014) Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2:690–698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sim F, Leidner R, Bell RB (2019) Immunotherapy for head and neck cancer. Oral Maxillofac Surg Clin North Am 31:85–100

    Article  PubMed  Google Scholar 

  • Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer Immunosurveillance and Immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50

    Article  CAS  PubMed  Google Scholar 

  • Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375–391

    Article  CAS  PubMed  Google Scholar 

  • Spranger S, Jeremias I, Wilde S, Leisegang M, Stärck L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ, Frankenberger B (2012) Tcr-transgenic lymphocytes specific for Hmmr/Rhamm limit tumor outgrowth in vivo. Blood 119:3440–3449

    Article  CAS  PubMed  Google Scholar 

  • Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (2011) Anti-Erbb-2 Mab therapy requires type I and II interferons and synergizes with anti-Pd-1 or anti-Cd137 Mab therapy. Proc Natl Acad Sci U S A 108:7142–7147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Steven A, Fisher SA, Robinson BW (2016) Immunotherapy for lung cancer. Respirology 21:821–833

    Article  PubMed  Google Scholar 

  • Sweeney C, Vyas P (2019) The graft-versus-leukemia effect in Aml. Front Oncol 9:1217

    Article  PubMed  PubMed Central  Google Scholar 

  • Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S (2017) Efficacy of adoptive immune-cell therapy in patients with advanced gastric cancer: a retrospective study. Anticancer Res 37:3947–3954

    CAS  PubMed  Google Scholar 

  • Tanyi JL, George E (2018) Personalized vaccination against ovarian cancer: what are the possibilities? Expert Rev Vaccines 17:955–958

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tao L, Huang G, Song H, Chen Y, Chen L (2017) Cancer associated fibroblasts: an essential role in the tumor microenvironment. Oncol Lett 14:2611–2620

    Article  PubMed  PubMed Central  Google Scholar 

  • Thrift AP, El-Serag HB (2020) Burden of gastric cancer. Clin Gastroenterol Hepatol 18:534–542

    Article  PubMed  Google Scholar 

  • Tun AM, Ansell SM (2020) Immunotherapy in Hodgkin and non-Hodgkin lymphoma: innate, adaptive and targeted immunological strategies. Cancer Treat Rev 88:102042

    Article  CAS  PubMed  Google Scholar 

  • Vandenput I (2011) Clinicopathologic study in uterine cancer. Facts Views Vis Obgyn 3:189–202

    CAS  PubMed  PubMed Central  Google Scholar 

  • Viale PH, Fung A, Zitella L (2005) Advanced colorectal cancer: current treatment and nursing management with economic considerations. Clin J Oncol Nurs 9:541–552

    Article  PubMed  Google Scholar 

  • von Witzleben A, Wang C, Laban S, Savelyeva N, Ottensmeier CH (2020) HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells. 9(9):2103. https://doi.org/10.3390/cells9092103. PMID: 32942747; PMCID: PMC7564543.

  • Vonderheide RH, Lorusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM (2010) Tremelimumab in combination with Exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible Costimulator expression on patient T cells. Clin Cancer Res 16:3485–3494

    Article  CAS  PubMed  Google Scholar 

  • Weiss SA, Wolchok JD, Sznol M (2019) Immunotherapy of melanoma: facts and hopes. Clin Cancer Res 25:5191–5201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Winters S, Martin C, Murphy D, Shokar NK (2017) Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci 151:1–32

    Article  CAS  PubMed  Google Scholar 

  • Xiao Q, Nobre A, Piñeiro P, Berciano-Guerrero MÁ, Alba E, Cobo M, Lauschke VM, Barragán I (2020) Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. J Clin Med. 9(1):286. https://doi.org/10.3390/jcm9010286. PMID: 31968651; PMCID: PMC7019273

  • Yan C, Tu XX, Wu W, Tong Z, Liu LL, Zheng Y, Jiang WQ, Zhao P, Fang WJ, Zhang HY (2019) Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe? World J Clin Cases 7:1253–1261

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL (2020) Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol 11:577869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5:288–300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang Y (2013) Epidemiology of esophageal cancer. World J Gastroenterol 19:5598–5606

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Sara Kamali Zonouzi

  2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Sara Kamali Zonouzi & Sepideh Razi

  3. School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    Sepideh Razi

  4. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Sepideh Razi & Nima Rezaei

  5. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  6. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Stockholm, Sweden

    Nima Rezaei

Authors
  1. Sara Kamali Zonouzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sepideh Razi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nima Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nima Rezaei .

Editor information

Editors and Affiliations

  1. Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Sweden

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Zonouzi, S.K., Razi, S., Rezaei, N. (2023). Introduction to Cancer Treatment. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_216-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80962-1_216-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80962-1

  • Online ISBN: 978-3-030-80962-1

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation